2. Selmi C., Gershwin M.E. The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 2009 Aug. 30 (8): 415–420.
3. Lindor K., Dickson R. Primary biliary cirrhosis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. 8th ed. Lippincott-Raven: Philadelphia; 1999. Vol 1: 679–692.
4. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006 Mar. 130 (3): 715–720.
5. Ricci P, Therneau T.M., Malinchoc M. et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology. 1997 Mar. 25 (3): 672–677.
Часть 2. Глава 11
1. Tsochatzis E.A., Bosch J., Burroughs A.K. Liver cirrhosis. Lancet. 2014 May 17. 383 (9930): 1749–1761.
2. Friedman S.L. Hepatic fibrosis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. 8th ed. Philadelphia, Pa: Lippincott-Raven; 1999. 371–385.
3. Freeman R.B. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection. Liver Transpl. 2004 Oct. 10 (10 Suppl 2): S2–3.
4. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug. 69 (2): 406–460.
5. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul. 69 (1): 182–236.
6. Lubel J.S., Angus P.W. Modern management of portal hypertension. Intern Med J. 2005 Jan. 35 (1): 45–49.
7. Sanyal A.J., Bosch J., Blei A., Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008 May. 134 (6): 1715–1728.
8. Kim T.Y., Jeong W.K., Sohn J.H., Kim J., Kim M.Y., Kim Y. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients. Liver Int. 2015 Nov. 35 (11): 2416–2424.
9. Sass D.A., Chopra K.B. Portal hypertension and variceal hemorrhage. Med Clin North Am. 2009 Jul. 93 (4): 837–853, vii-viii.
10. Arroyo V., Gines P., Gerbes A.L. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996 Jan. 23 (1): 164–176.
11. Caldwell S.H., Battle E.H. Ascites and spontaneous bacterial peritonitis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. 8th ed. Philadelphia, Pa: Lippincott-Raven; 1999. 371–385.
12. Kiser T.H., Maclaren R., Fish D.N. Treatment of hepatorenal syndrome. Pharmacotherapy. 2009 Oct. 29 (10): 1196–1211.
13. Hou W., Sanyal A.J. Ascites: diagnosis and management. Med Clin North Am. 2009 Jul. 93 (4): 801–817, vii.
14. Ahboucha S., Pomier-Layrargues G., Butterworth R.F. Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy. Metab Brain Dis. 2004 Dec. 19 (3–4): 241–51.
15. Ahboucha S., Butterworth R.F. The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy. Metab Brain Dis. 2007 Dec. 22 (3–4): 291–308.
16. Butterworth R.F. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol. 2016 Jun. 160: 94–97.
17. Shawcross D.L., Dunk A.A., Jalan R. et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016 Feb. 28 (2): 146–152.
18. Frederick R.T. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y). 2011 Apr. 7 (4): 222–233.
Часть 2. Глава 12
1. Onori P., Franchitto A., Mancinelli R. et al. Polycystic liver diseases. Dig Liver Dis. 2010 Apr. 42 (4): 261–271.
2. Choi H.K., Lee J.K., Lee K.H. et al. Differential diagnosis for intrahepatic biliary cystadenoma and hepatic simple cyst: significance of cystic fluid analysis and radiologic findings. J Clin Gastroenterol. 2010 Apr. 44 (4): 289–293.
3. Mazza O.M., Fernandez D.L., Pekolj J. et al. Management of nonparasitic hepatic cysts. J Am Coll Surg. 2009 Dec. 209 (6): 733–739.
4. Amendolara M., Bucca D., Barbarino C., Romano M.F., Marino G., Zucchelli M. et al. Surgical management of symptomatic simple hepatic cysts. G Chir. 2012 Jan-Feb. 33 (1–2): 17–20.
5. Schnelldorfer T., Torres V.E., Zakaria S. et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg. 2009 Jul. 250 (1): 112–118.
6. Dickie B., Dasgupta R., Nair R. et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009 Jan. 44 (1): 125–133.
7. Giannitrapani L., Soresi M., La Spada E. et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci. 2006 Nov. 1089: 228–236.
8. Bajenaru N., Balaban V., Savulescu F., Campeanu I., Patrascu T. Hepatic hemangioma – review-. J Med Life. 2015. 8 Spec Issue: 4–11.
9. Hasan H.Y., Hinshaw J.L., Borman E.J., Gegios A., Leverson G., Winslow E.R. Assessing normal growth of hepatic hemangiomas during long-term follow-up. JAMA Surg. 2014 Dec. 149 (12): 1266–1271.
10. Jing L., Liang H., Caifeng L. et al. New recognition of the natural history and growth pattern of hepatic hemangioma in adults. Hepatol Res. 2016 Jul. 46 (8): 727–733.
11. Albiin N. MRI of focal liver lesions. Curr Med Imaging Rev. 2012 May. 8(2): 107–116.
12. Plackett T.P., Lin-Hurtubise K.M. Hepatic hemangiomas and parachuting. Aviat Space Environ Med. 2008 Oct. 79 (10): 986–988.
